Literature DB >> 32043647

Polymorphisms associated with optimization of biological therapy through drug dose reduction in moderate-to-severe psoriasis.

F Abad-Santos1,2, E Daudén3, M C Ovejero-Benito1, E Muñoz-Aceituno3, D Sabador1, A Reolid3, M Llamas-Velasco3, R Prieto-Pérez1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 32043647     DOI： 10.1111/jdv.16256

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN： 0926-9959            Impact factor:   6.166


× No keyword cloud information.
  3 in total

Review 1.  Pharmacogenetics Update on Biologic Therapy in Psoriasis.

Authors:  Ester Muñoz-Aceituno; Luisa Martos-Cabrera; María Carmen Ovejero-Benito; Alejandra Reolid; Francisco Abad-Santos; Esteban Daudén
Journal:  Medicina (Kaunas)       Date:  2020-12-20       Impact factor: 2.430

Review 2.  Towards Personalized Medicine in Psoriasis: Current Progress.

Authors:  Elisa Camela; Luca Potestio; Angelo Ruggiero; Sonia Sofia Ocampo-Garza; Gabriella Fabbrocini; Matteo Megna
Journal:  Psoriasis (Auckl)       Date:  2022-09-01

3.  Attitudes and behaviour regarding dose reduction of biologics for psoriasis: a survey among dermatologists worldwide.

Authors:  M E van Muijen; L S van der Schoot; J M P A van den Reek; E M G J de Jong
Journal:  Arch Dermatol Res       Date:  2021-08-31       Impact factor: 3.033
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.